Navigation Links
11th International Congress on Targeted Anticancer Therapies
Date:2/28/2013

Lugano/Amsterdam, 28 February 2013 -- A range of new and promising targeted drugs currently under development for improved cancer therapy will be presented during the 11th International Congress on Targeted Anticancer Therapies, Paris, 4-6 March 2013 (TAT 2013). The event, which is organised by NDDO Education Foundation, is an ESMO Partnership Meeting, co-sponsored by the U.S. National Cancer Institute.

Over 500 oncologists and scientists from all over the world will review and discuss cancer therapies of the future. Among them, many top academic experts involved in the early-phase clinical development of new targeted therapeutics and molecular cancer diagnostics, the cornerstones of personalised cancer therapy .

Personalised cancer medicine: targets and therapeutics

The development of new targeted cancer therapies is one of the main drivers for the further evolution of personalized cancer medicine. The concept of personalized medicine is based upon the notion that cancer development and progression are driven by genomic abnormalities and that these abnormalities are different not only between different types of cancer, but also between individual patients. Such findings have opened the door to the development of targeted cancer therapeutics, directed against tumour-specific molecular abnormalities.

At TAT 2013, over 50 plenary lectures and 70 posters will address dozens of emerging targeted agents and new drug targets under development for cancer therapy. In particular targets and experimental therapeutics in the early stages of clinical and the late stages of preclinical development will be addressed.

Program Highlights

  • Keynote Lecture "Targeting immune checkpoints in cancer therapy" (Michael B. Atkins, Washington, DC);
  • "New immune checkpoints as targets", featuring updates on four promising global drug development programmes targeting the immune system in cancer patients;
  • "Metabolic drug targets", featuring updates on three major drug development programmes trying to exploit abnormalities in tumour cell metabolism;
  • "Phase 1 studies, completed or in progress", featuring seven targeted drugs in phase 1, including brand-new data;
  • "Whole-genome sequencing in early-phase drug development", addressing issues around the implementation of genomics already in the early clinical phases of drug development in order to better identify patients that will benefit from the new drug;
  • NDDO Honorary Award Lecture 2013 "Phase 1, a critical step for cancer drug development" (Jean-Pierre Armand, Paris, France)


'/>"/>
Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related biology news :

1. Ultracold matter technology from CU and SRI International licensed to Boulders ColdQuanta
2. International Polar Year conference: From knowledge to action
3. Large international study finds memory in adults impacted by versions of 4 genes
4. International team uncovers new genes that shape brain size, intelligence
5. Southampton researchers lead 2 international projects to help people out of poverty
6. UCSD researchers: Where international climate policy has failed, grassroots efforts can succeed
7. Washington University receives $8 million to lead international childhood malnutrition effort
8. Early Bird Discounts Available on International Healthcare and Biotechnology Conferences, Save Up To $600 with Global Information
9. New HealthFocus® International Study Reveals Five Very Different Weight Management Consumers
10. OU scientists and international team deciper the genetic code of the tomato
11. Digicel Launches Worlds First Biometric Identification System For International Money Transfers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2017)... -- Delta ID Inc., a leader in consumer-grade iris scanning ... CES® 2017. Delta ID has collaborated with Gentex Corporation ... of iris scanning as a secure, reliable and convenient ... car, and as a way to elevate the security ... ID and Gentex will demonstrate (booth #7326 LVCC) a ...
(Date:12/22/2016)... 2016  As part of its longstanding mission to improve ... company, recently released its latest children,s book, titled ... on the topics of inheritance and variation of traits that ... in elementary school classrooms in the US. ... Ariana Killoran , whose previous book with 23andMe, ...
(Date:12/19/2016)... BARCELONA , España y TORONTO , 19 ... fusión con Northern Biologics Inc. que permitirá el desarrollo acelerado de ... ensayos clínicos en varios tipos de tumor en 2017, con múltiples ... ... de su clase con objetivo en el factor inhibidor de leucemia ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... Jan. 18, 2017 Shareholder rights law firm ... whether the board members of CoLucid Pharmaceuticals, Inc. (NASDAQ: ... connection with the proposed sale of the Company to ... that develops small molecules for the acute treatment of ... it had signed a definitive merger agreement with Eli ...
(Date:1/18/2017)... - SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: SQIDF) ... and commercializes proprietary technologies and products for advanced ... that Cameron Prange , President of Kingsdale ... Board of Directors.  Mr. Prange,s resignation is related ... limited both his ability to act on behalf ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... Balance™ GT soybeans. The new Balance™ GT Soybean Performance System will combine industry-leading ... isoxaflutole, the active ingredient in the new Balance® Bean herbicide. The Balance™ GT ...
(Date:1/17/2017)... Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... detection of foodborne pathogens today announced the appointment of Mary ... Thomas , the Company,s President and CEO since 2009, who will ... The changes are effective today. In addition, Ms. Duseau ... ...
Breaking Biology Technology: